DNL593
AssetAlso TAK-594, PTV:PGRN
Blood-brain-barrier-crossing progranulin replacement protein
- Stage
- Phase 1
- Modality
- Protein or enzyme
- Target
- Proteostasis
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Frontotemporal dementia
Phase 1, investors.denalitherapeutics.com, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets2
- Competitors3
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.